Jenburkt Pharmaceuticals Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Jenburkt Pharmaceuticals Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Cash, after subtracting all debt, equals 12% of its market value (net cash). Higher than 92% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹67Over the last 3 years, every ₹100 of reported profit came with ₹67 of operating cash.
Lower than 78% of Healthcare companies in India.
Self-Funding Ratio
1.7×Over the last 3 years its own operating cash covered its investment spending (capex) 1.7 times.
Higher than 63% of Healthcare companies in India.
Cash Locked Ratio
₹14For every ₹100 of sales, ₹14 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹10 tied up three years earlier.
Less money tied up than 69% of Healthcare companies in India.
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 83% of Healthcare companies in India.
Growth Efficiency Ratio
₹31Sales grew 24% in 3 years; of every extra ₹100 of sales, ₹31 became extra profit.
Higher than 78% of Healthcare companies in India.
Asset Productivity Ratio
+24% / +59%In 3 years sales changed by +24% while total assets changed by +59%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
No debt dueNo debt falls due within a year, according to the latest yearly balance sheet.
Cash Cushion Ratio
+12%Cash, after subtracting all debt, equals 12% of its market value (net cash).
Higher than 92% of Healthcare companies in India.
Tangible Assets Ratio
100%Of every ₹100 the company owns, ₹100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 80% of Healthcare companies in India.
Tangible Net Worth Ratio
100%Of every ₹100 of net worth, ₹100 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 83% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Jenburkt Pharmaceuticals Limited owes ₹0.13 for every ₹1 it owns. Net profit rose 8% in the year to Mar 2026, and grew 12% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
11.7Investors pay ₹11.7 for every ₹1 of Jenburkt Pharmaceuticals Limited's yearly profit, lower than 93% of Healthcare companies in India.
P/B ratio
1.95The share price is 1.95 times Jenburkt Pharmaceuticals Limited's book value per share, lower than 89% of Healthcare companies in India.
Market cap
₹385 CrThe total market value of all of Jenburkt Pharmaceuticals Limited's shares at today's price (share price × number of shares), smaller than 88% of Healthcare companies in India. PosiCap size class: Micro Cap.
Net worth (book value)
₹197 CrWhat Jenburkt Pharmaceuticals Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹446.47Net worth divided by the number of shares. The share price of ₹871.40 is 2.0 times this, which is the P/B above.
Return on equity (ROE)
16.7%Jenburkt Pharmaceuticals Limited earned 16.7% on its shareholders' money over the last year, higher than 65% of Healthcare companies in India.
Owes vs Owns
0.13×Jenburkt Pharmaceuticals Limited owes ₹0.13 for every ₹1 it owns (low), lower than 95% of Healthcare companies in India.
Dividend yield
2.25%Jenburkt Pharmaceuticals Limited pays 2.25% of its share price as dividends a year, higher than 96% of dividend-paying Healthcare companies in India.
Revenue growth
+11%Revenue rose 11% in the year to Mar 2026, and grew 7% a year on average over 3 years.
Profit growth
+8%Net profit rose 8% in the year to Mar 2026, and grew 12% a year on average over 3 years.
Profit margin
20.6%Jenburkt Pharmaceuticals Limited keeps ₹21 of every ₹100 of revenue as net profit.
Cash quality
0.8×Cash from Jenburkt Pharmaceuticals Limited's business was 0.8× its reported profit in the year to Mar 2026 — less cash came in than the profit reported.
Interest cover
109.2×Jenburkt Pharmaceuticals Limited's operating profit covered its interest costs 109.2 times in the year to Mar 2026.
Cash vs debt
Net cashJenburkt Pharmaceuticals Limited held ₹45 Cr more cash than debt (net cash) at Mar 2026.
Questions
What is Jenburkt Pharmaceuticals Limited's P/E ratio?
Investors pay ₹11.7 for every ₹1 of Jenburkt Pharmaceuticals Limited's yearly profit, lower than 93% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Jenburkt Pharmaceuticals Limited: ₹385 Cr ÷ ₹197 Cr (31 Mar 2026) = 2.0.
What is Jenburkt Pharmaceuticals Limited's return on equity?
Jenburkt Pharmaceuticals Limited earned 16.7% on its shareholders' money over the last year, higher than 65% of Healthcare companies in India.
How much does Jenburkt Pharmaceuticals Limited owe compared with what it owns?
Jenburkt Pharmaceuticals Limited owes ₹0.13 for every ₹1 it owns (low), lower than 95% of Healthcare companies in India.
Does Jenburkt Pharmaceuticals Limited pay a dividend?
Yes. Jenburkt Pharmaceuticals Limited pays 2.25% of its share price as dividends a year, higher than 96% of dividend-paying Healthcare companies in India.
Is Jenburkt Pharmaceuticals Limited's revenue growing?
Revenue rose 11% in the year to Mar 2026, and grew 7% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.